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Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) have emerged as important
drug targets for diabetes. Drugs that activate PPARγ, such as the thiazolidinediones (TZDs), are
widely used for treatment of Type 2 diabetes mellitus. PPARγ signaling could also play an anti-
neoplastic role in several in vitro models, although conflicting results are reported from in vivo
models. The effects of TZDs on cancer risk in humans needs to be resolved as these drugs are
prescribed for long periods of time in patients with diabetes.
Methods: A total of 1003 subjects in community practice settings were interviewed at home at
the time of enrolment into the Vermont Diabetes Information System, a clinical decision support
program. Patients self-reported their personal and clinical characteristics, including any history of
malignancy. Laboratory data were obtained directly from the clinical laboratory and current
medications were obtained by direct observation of medication containers. We performed a cross-
sectional analysis of the interviewed subjects to assess a possible association between cancer
diagnosis and the use of TZDs.
Results:  In a multivariate logistic regression model, a diagnosis of cancer was significantly
associated with TZD use, even after correcting for potential confounders including other oral anti-
diabetic agents (sulfonylureas and biguanides), age, glycosylated hemoglobin A1C, body mass index,
cigarette smoking, high comorbidity, and number of prescription medications (odds ratio = 1.59, P
= 0.04). This association was particularly strong among patients using rosiglitazone (OR = 1.89, P
= 0.02), and among women (OR = 2.07, P = 0.01).
Conclusion: These data suggest an association between TZD use and cancer in patients with
diabetes. Further studies are required to determine if this association is causal.
Background
Factors affecting cancer incidence in the diabetic popula-
tion are diverse and complex. Diabetes is a risk factor for
colon, pancreas, breast, endometrium and liver cancer in
women. In men, although diabetes it is a risk factor for
bladder cancer [1,2], it is a protective factor for prostate
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cancer [3], particularly in those receiving anti-diabetic
treatment [4,5]. One of the limitations of such observa-
tional studies is that most have not examined the poten-
tial association between medication use and cancer risk.
The increasing prevalence of diabetes has intensified the
search for new therapies. Orally administered anti-dia-
betic agents (oral agents) can be used alone or in combi-
nation with other oral agents or insulin [6]. Over the last
decade, the gamma subtype of the peroxisome prolifera-
tor-activated receptors (PPARγ), has emerged as an impor-
tant drug target in diabetes [7]. PPARγ agonists currently
used as oral agents are thiazolidinedione (TZD) drugs,
including rosiglitazone and pioglitazone.
The TZDs are attractive options in the therapy of diabetes
because they decrease insulin resistance [8-10]. In addi-
tion to being a therapeutic option in diabetes, PPARγ ago-
nists are now believed to be a potential strategy for
treatment of several cancers [11,12]. Although differential
expression of PPARγ is observed in tumors compared to
normal tissues, and PPARγ agonists have been shown to
inhibit tumor cell growth and survival, the interdepend-
ence of these observations is unclear. Conflicting results
on the pro-carcinogenic and anti-tumorigenic role of
PPARγ agonists such as the TZDs can be found in the liter-
ature. Some of the anti-tumorigenic effects of TZDs have
been demonstrated in colon cancer cells [13], glioma cells
in vivo [14], lung cancer cells [15,16], thyroid carcinoma
cells [17], hepatocellular carcinoma [18] and others.
However, some studies have shown pro-carcinogenic
roles for TZDs. Saez et al showed that the use of a TZD
increased the number of polyps in the colon of mice [19].
Seargent, Yates and Gill [20] demonstrated that the PPARγ
antagonist GW9662 inhibited growth of human mam-
mary tumor cell lines. Surprisingly, GW9662 prevented
rosiglitazone-mediated PPARγ activation, but enhanced
rosiglitazone-induced growth inhibition [20]. As such,
these data support the existence of PPARγ-independent
pathways and challenge the belief that TZDs mediate their
effects only via activation of PPARγ. These conflicting
results must be resolved, as the possible pro-carcinogenic
effects of TZDs raise questions about their long-term
safety in patients.
Evidence of both pro-carcinogenic and anti-tumorigenic
effects of PPARγ agonists have been mainly studied in vitro
and in vivo models that do not take into full account the
metabolic characteristics of patients with diabetes.
Recently, a population-based report showed that TZDs
were associated with reduced risk of lung cancer in dia-
betic patients [21] in agreement with previous in vitro
studies [15,16]. Here, we report the association between
anti-diabetic therapies, particularly TZDs, and cancer
prevalence in diabetic patients participating in the Ver-
mont Diabetes Information System (VDIS).
Methods
This study is part of a larger project, the Vermont Diabetes
Information System (VDIS), a study of 8855 adults with
diabetes in primary care practices [22]. The subjects com-
prised all diabetic adults in 69 practices in Vermont and
adjacent New Hampshire and New York. A field survey
was completed at study baseline with a sub-sample of sub-
jects in order to provide a better understanding of the
non-laboratory features of diabetes. Patients' names were
randomly sorted and patients contacted by telephone
until a sample of approximately 15% of patients from
each practice agreed to participate in the field survey to
give a sample of 1007 at the time of analysis. Four patients
were dropped from the analysis due to incomplete infor-
mation, leaving a final sample of 1003.
Subjects completed a questionnaire at home and then
were visited by a trained research assistant who reviewed
the questionnaire responses, assisted the subject with any
missing or unacceptable responses, reviewed the subject's
medications, and measured their height and weight using
a portable stadiometer and scale. Race, education,
income, marital status, functional status, smoking, alco-
hol consumption and comorbid conditions were
obtained by questionnaire. Prior to the interview, patients
were instructed to gather all current medications, includ-
ing over the counter preparations, for review by the
research assistant. The medication list was ascertained by
direct observation of the medication container with
recording of the drug name, dose, frequency and route of
administration. Duration of therapy was not recorded.
We used the SF-12 health survey to determine physical
and mental functional status. Results were scored and nor-
malized using designed algorithms and expressed in terms
of the Physical Component Summary (PCS) and the Men-
tal Component Summary (MCS) [23]. To determine
comorbidity, we used a modification of the Self-Adminis-
tered Comorbidity Questionnaire [24] in which we asked
each patient to indicate whether they have had the follow-
ing conditions: heart attack, heart failure, peripheral arte-
rial disease, stroke, dementia, chronic obstructive lung
disease, rheumatic disease, peptic ulcer, cirrhosis, paraly-
sis, renal insufficiency, diabetic vascular complications,
AIDS/HIV and depression. All patients also had diabetes,
which was not included in the comorbidity count.
Patients with two or more comorbid conditions were con-
sidered "high comorbidity". Patients were classified as
having cancer if they reported any cancer, leukemia, or
lymphoma. Specific cancer sites and dates of diagnosis
were not recorded.BMC Medicine 2007, 5:17 http://www.biomedcentral.com/1741-7015/5/17
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The interviews occurred between July 2003 and March
2005. Most laboratory data were obtained from the
patients' local clinical laboratories, which all use the same
Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications high per-
formance, liquid chromatography (HPLC) method for the
determination of glycosylated hemoglobin (A1C). Less
than 1% of A1C tests were performed using the Bayer DCA
2000 immunoassay point of care instrument, which has
been shown to compare favorably with the HPLC method
[25].
The research protocol was carried out in compliance with
the Helsinki Declaration and was approved by the Com-
mittee on Human Research of the University of Vermont.
The interviewed subjects provided written informed con-
sent. The full study protocol and variables and the medi-
cation profiles of the subjects have been previously
reported [22,26].
Statistical approach
We performed a cross-sectional analysis of the inter-
viewed subjects at the time of their enrollment in the VDIS
trial. We explored the association between cancer and the
use of oral agents, using logistic regression with history of
cancer as the outcome variable and the use of TZDs as the
primary predictor variable. We then adjusted for possible
confounding by social and clinical factors. Potential con-
founders tested were: other oral anti-diabetic agents (sul-
fonylureas and biguanides; yes/no), gender, age (years),
race (white/other), glycosylated hemoglobin level (A1C;
mg %), insulin use (yes/no), body mass index (BMI; kg/
m2), alcohol drinking (yes/no), cigarette smoking (yes/
no), income (in eight ordered categories), duration of dia-
betes in years, high comorbidity (two or more comorbid
conditions), number of prescription medications,
number of anti-diabetic drugs, physical function status
and mental function status. To reduce the number of var-
iables in the final model, we excluded potential con-
founders that were associated with the outcome in
univariate analyses with P > 0.2. Such weak association
argues that the variable is unlikely to be a confounder.
However, variables representing use of TZDs, sulfonylu-
reas and biguanides were included regardless of their P-
values. Because diabetes is associated with an increased
incidence of breast and endometrial cancers and a
reduced incidence of prostate cancers [2-4], we also per-
formed separate multivariate analyses for men and
women. Because the effects of TZDs on cancer might be
mediated through pathways other than PPARγ, and there-
fore not be an effect of all TZDs, we also performed sepa-
rate analyses for pioglitazone and rosiglitazone. We used
Stata/SE v.9.2 (StataCorp, College Station, TX, USA) for all
analyses.
Results
The general characteristics of the study population are
described in Table 1. The study population is representa-
tive of adults with diabetes in primary care practices in
Northern New England, USA. Because many of the sub-
jects are over retirement age or suffer disability from
chronic conditions, their income is lower than healthy
younger Americans.
The number of cancer patients in this population was 126
(12.6%). A total of 26% of the subjects used a TZD,
including 13.6% on pioglitazone and 12.8% on rosiglita-
zone (Table 1).
Table 2 presents univariate associations between cancer
diagnosis and the other study variables. Rosiglitazone,
age, high comorbidity, and number of prescription medi-
cations were significantly associated with cancer preva-
lence.
Next, potential confounding variables associated with
cancer with P < 0.2 and all oral agents regardless of their
P-value were included in a logistic regression model using
cancer as the outcome. These included TZD therapy, sul-
fonylurea therapy, biguanide therapy, age, glycosylated
hemoglobin (A1C), BMI (kg/m2), cigarette smoking, high
Table 1: Baseline characteristics of 1003 adults with diabetes
Characteristic n (%) or mean (sd)
History of cancer 126 (12.6%)
TZD therapy 263 (26.2%)
Pioglitazone 136 (51.3%)
Rosiglitazone 128 (48.7%)
Any TZD alone -71 (27.0%)
TZD and biguanide -65 (24.7%)
TZD and sulfonylurea -56 (21.3%)
TZD and biguanide and sulfonylurea -71 (27.0%)
Gender:
Men 457 (45.6%)
Women 546 (54.4%)
Age, years 64.8 (12.0)
White ethnicity 973 (97.3%)
Glycosolated hemoglobin A1C, % 7.13 (1.3)
Insulin use 185 (18.4%)
Body mass index, kg/m2 33.81 (7.4)
Alcohol use 274 (27.4%)
Cigarette smoking 170 (16.9%)
Median annual income, $ 15000–29999
Duration of diabetes, years 10.2 (10.3)
High comorbidity 495 (49.4%)
Number of prescription medications 6.7 (3.8)
Number of anti-diabetic medications 1.2 (0.9)
Physical functional status 41.2 (12.4)
Mental functional status 50.0 (10.7)
TZD, thiazolidinedione; sd, standard deviation; n, number of subjects 
with the characteristic.BMC Medicine 2007, 5:17 http://www.biomedcentral.com/1741-7015/5/17
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comorbidity conditions, and number of prescription
medications. This model showed a significant association
between cancer and the use of any TZD (OR = 1.59, 95%
CI (1.03–2.44), P = 0.04) (Table 3). A significant associa-
tion was found for rosiglitazone (OR = 1.89, 95% CI
(1.11–3.19), P = 0.02) (Table 3), but not for pioglitazone
(OR = 1.09, 95% CI (0.62–1.94), P = 0.76) (Table 3).
Other variables significantly associated with cancer his-
tory include age and high comorbidity (Table 3).
When the analysis was stratified by gender, it showed a
highly significant association between cancer prevalence
and TZDs in women (OR = 2.07, 95% CI (1.18–3.63), P =
0.01) (Table 4), but not in men (OR = 1.20, 95% CI
(0.58–2.46), P = 0.63) (Table 4).
TZDs are used alone or in combination with other oral
anti-diabetic agents (Table 1). The multivariate analyses
found no evidence for the use of other oral agents con-
founding the relationship of TZD therapy with cancer
(Table 3), but in the gender stratified analysis, the use of
sulfonylurea is negatively associated with cancer in
women (OR = 0.49, 95% CI (0.27–0.89),P = 0.02) (Table
4). Other variables significantly associated with cancer
history in women included high comorbidity (OR = 2.90,
95% CI (1.56–5.41),P = 0.001) and number of prescrip-
tion medications(OR = 1.09, 95% CI (1.01–1.18),P  =
0.03) (Table 4). Similarly, in men, high comorbidity (OR
= 4.29, 95% CI (2.11–8.72),P < 0.001) and number of
prescription medications(OR = 0.89, 95% CI (0.80–
0.98),P = 0.02) were associated with cancer history (Table
4).
Discussion
We have demonstrated an association between the use of
TZDs and cancer in a community-based population of
adults with diabetes. The association was observed prima-
rily among rosiglitazone users and not among subjects
using pioglitazone. Furthermore, the association was
found in women, but not men.
The gender-dependent observation is difficult to explain.
TZDs have gained widespread use in polycystic ovary syn-
drome (PCOS) [27] that has been correlated with
endometrial cancer [28]. Perhaps the TZDs are not caus-
ing cancer, but are used by patient with cancers caused by
PCOS. It is worth noting that as the average age in this
population is post-menopausal, the use of TZDs for PCOS
is probably low. Unfortunately, we do not have data on
the history of PCOS in these patients. More alarmingly, it
is possible that TZDs disrupt estrogen pathways and
increase the incidence of hormone-sensitive tumors such
as those of the breast and endometrium. We do not know
which specific tumors are increased in the TZD users in
this population.
Likewise, we are not aware of a convincing explanation or
previous results to support the finding in this study of an
Table 2: Univariate associations between cancer and other patient characteristics
Characteristic Cancer patients Non-cancer patients Odds ratio P
% or mean (sd) n % or mean (sd) n
Number of subjects 126 877
TZD therapy 32.5% 126 25.3% 877 1.42 0.09
Pioglitazone 13.5% 126 13.6% 877 0.99 0.98
Rosiglitazone 19.1% 126 11.9% 877 1.75 0.03
Sulfonylurea therapy 34.9% 126 38.2% 877 0.87 0.48
Biguanide therapy 39.7% 126 40.0% 877 0.99 0.94
Nateglinide therapy 0.8% 126 0.5% 877 1.75 0.62
Men 42.1% 126 46.1% 877 0.85 0.40
Age, years 69.1 (10.2) 126 64.2 (12.1) 877 1.04 <0.001
White ethnicity 97.6% 125 97.3% 875 1.15 0.83
A1C, mean % 7.0 (1.3) 126 7.2 (1.3) 871 0.88 0.12
Insulin therapy 15.9% 126 18.8% 877 0.81 0.43
Body mass index, kg/m2 32.7 (6.8) 125 34.0 (7.5) 865 0.97 0.06
Alcohol drinking 25.4% 126 27.6% 876 0.89 0.60
Cigarette smoking 11.1% 126 17.8% 876 0.58 0.06
Median annual income, $ 15000–29999 114 15000–29999 813 1.02 0.75
Duration of diabetes, years 10.2 (9.7) 124 10.2 (10.4) 829 1.00 0.98
High comorbidity 71.4% 126 46.2% 877 2.91 <0.001
Number of prescription medications 7.3 (4.3) 126 6.6 (3.7) 877 1.05 0.05
Number of anti-diabetic drugs 1.2 (1.0) 126 1.2(0.9) 877 1.01 0.92
Physical functional status 40.9 (13.7) 125 42.3 (12.7) 871 0.99 0.27
Mental functional status 50.5 (10.5) 126 49.4 (10.9) 875 1.01 0.30
sd, standard deviation; n, number of patients for which data were available; TZD, thiazolidinedione.BMC Medicine 2007, 5:17 http://www.biomedcentral.com/1741-7015/5/17
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association with cancer for rosiglitazone, but not pioglita-
zone. As both are thought to activate PPARγ with similar
potency, this finding suggests another mechanism for the
association. Furthermore, we cannot explain the differ-
ences found between the anti-cancer effect of PPARγ acti-
vation in vitro and our results. Some studies suggest that
natural mutant PPARγ alleles might impair native PPARγ
function [29] and differences in the PPARγ genotype
could modify the response to TZD treatment. Further
studies incorporating rigorous controls for genetic and
environmental confounders are required to identify the
molecular mechanisms involved in the differences found
between the two drugs and the discrepancies with in vitro
studies.
Cancer patients used slightly more prescription medica-
tions than non-cancer patients, but similar numbers of
anti-diabetic medications (Table 2). This is consistent
with the need for additional anti-cancer therapies as deter-
mined from the prescription drug list of cancer patients
compared to non-cancer patients. Cigarette smoking is
somewhat less prevalent in the cancer patients than the
non-cancer patients, in spite of the well-known associa-
tion of tobacco use and cancer incidence. This could be
because cancer survivors are highly motivated to quit
smoking [30], or that smokers with cancer die at a higher
rate than non-smokers with cancer [31].
We note that cancer patients tended to have more comor-
bid conditions than non-cancer patients. This could be
due to the well-known associations between some of the
specific measured comorbidities and various cancers. For
instance, chronic obstructive lung disease and cirrhosis
are often associated with lung cancer and hepatoma,
respectively [32,33].
To further address potential confounding, we also
included two other common oral anti-diabetic agents
(sulfonylureas and biguanides). Results presented here
showed no significant association of either class of medi-
cations with cancer prevalence or any confounding of the
association between TZDs and cancer in the general
model (Table 3). However, a protective effect of sulfony-
lurea therapy for women was found in the gender-strati-
fied model (Table 4). The fact that we observe an
Table 4: Multivariate logistic regression of dependent variable 
cancer versus any TZD therapy (Rosiglitazone or Pioglitazone) 
and potential confounders stratified by gender
Odds ratio P 95% CI
Women (N = 535)
TZD therapy 2.07 0.01 1.18–3.63
Age 1.02 0.25 0.99–1.04
Biguanide use 1.63 0.09 0.93–2.84
Sulfonylurea use 0.49 0.02 0.27–0.89
Glycosolated hemoglobin A1C, % 0.94 0.59 0.76–1.17
Body mass index, kg/m2 0.97 0.07 0.93–1.00
Cigarette smoking 0.43 0.06 0.18–1.03
High comorbidity conditions 2.90 0.001 1.56–5.41
Number of prescription 
medications
1.09 0.03 1.01–1.18
Men (N = 448)
TZD therapy 1.20 0.63 0.58–2.46
Age 1.05 0.01 1.01–1.08
Biguanide use 0.99 0.97 0.51–1.91
Sulfonylurea use 1.22 0.56 0.63–2.35
Glycosolated hemoglobin A1C, % 0.83 0.22 0.62–1.12
Body mass index, kg/m2 0.97 0.32 0.91–1.03
Cigarette smoking 0.78 0.62 0.30–2.03
High comorbidity conditions 4.29 <0.001 2.11–8.72
Number of prescription 
medications
0.89 0.018 0.80–0.98
TZD, thiazolidinedione.
Table 3: Multivariate logistic regression: cancer vs. TZD therapy 
and potential confounders including combined oral anti-diabetic 
treatments
Odds ratio P 95% CI
Any TZD therapy (N = 983) 1.59 0.04 1.03–2.44
Age 1.03 0.01 1.01–1.05
Biguanide therapy 1.37 0.14 0.90–2.10
Sulfonylurea therapy 0.70 0.09 0.45–1.05
Glycosolated hemoglobin A1C, % 0.91 0.30 0.76–1.08
Body mass index, kg/m2 0.97 0.08 0.94–1.00
Cigarette smoking 0.61 0.13 0.33–1.15
High comorbidity conditions 3.40 <0.001 2.14–5.39
Number of prescription 
medications
1.01 0.97 0.95–1.07
Rosiglitazone therapy (N = 
983)
1.89 0.02 1.11–3.19
Age 1.03 0.05 1.01–1.05
Biguanide therapy 1.34 0.16 0.89–2.04
Sulfonylurea therapy 0.70 0.10 0.46–1.07
Glycosolated hemoglobin A1C, % 0.92 0.34 0.77–1.09
Body mass index, kg/m2 0.97 0.09 0.94–1.00
Cigarette smoking 0.61 0.13 0.33–1.15
High comorbidity conditions 3.32 <0.001 2.10–5.26
Number of prescription 
medications
1.00 0.92 0.95–1.06
Pioglitazone therapy (N = 
983)
1.09 0.76 0.62–1.94
Age 1.03 0.01 1.01–1.05
Biguanide 1.41 0.11 0.93–2.13
Sulfonylureas 0.71 0.12 0.47–1.09
Glycosolated hemoglobin A1C, % 0.91 0.27 0.77–1.08
Body mass index, kg/m2 0.98 0.12 0.91–1.01
Cigarette smoking 0.62 0.13 0.33–1.15
High comorbidity conditions 3.36 <0.001 2.12–5.32
Number of prescription 
medications
1.01 0.81 0.95–1.07
TZD, thiazolidinedione.BMC Medicine 2007, 5:17 http://www.biomedcentral.com/1741-7015/5/17
Page 6 of 7
(page number not for citation purposes)
association with cancer for some PPARγ agonists (TZDs),
but not others (sulfonylureas; [34]) suggests the notion of
PPARγ-independent mechanisms in the association
between TZDs and cancer.
This study has several strengths. First, the interviewed sub-
jects were a randomly selected subset of a large population
of patients receiving care in the Northeast USA, and are
therefore likely to be representative of primary care
patients. Second, all data on medications were obtained
by direct observation in the patient's home and not from
secondary sources.
This study does however also have several limitations,
including lack of confirmation of the cancer diagnoses,
and lack of information on the time relation between
onset of cancer and the use of TZDs or the duration of
treatment. In addition, information on the type or stage of
the cancer cases is missing, and skin cancers are not
reported. As in any cross-sectional study, unmeasured
confounders could be responsible for the apparent associ-
ations found.
Conclusion
Our findings suggest a possible association between can-
cer and the use of TZDs, particularly rosiglitazone, and
particularly among women, but this association requires
further investigation.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors contributed equally to this work
Acknowledgements
This research was supported by NIH grants RO1 DK61167, K24 
DK068380 (BL), and NCI grant K01 CA104159-01 (MERN).
References
1. Schiel R, Beltschikow W, Steiner T, Stein G: Diabetes, insulin, and
risk of cancer.  Methods Find Exp Clin Pharmacol 2006, 28:169-175.
2. Khan M, Mori M, Fujino Y, Shibata A, Sakauchi F, Washio M, Tamako-
shi A: Site-specific cancer risk due to diabetes mellitus his-
tory: evidence from the Japan Collaborative Cohort (JACC)
Study.  Asian Pac J Cancer Prev 2006, 7:253-259.
3. Rosenberg DJ, Neugut AI, Ahsan H, Shea S: Diabetes mellitus and
the risk of prostate cancer.  Cancer Invest 2002, 20:157-165.
4. Gonzalez-Perez A, Garcia Rodriguez LA: Prostate cancer risk
among men with diabetes mellitus (Spain).  Cancer Causes Con-
trol 2005, 16:1055-1058.
5. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE: Dia-
betes and risk of prostate cancer in a prospective cohort of
US men.  Am J Epidemiol 2005, 161:147-152.
6. Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type
2 diabetes mellitus.  Can Med Assoc J 2005, 172:213-226.
7. Savkur RS, Miller AR: Investigational PPAR-gamma agonists for
the treatment of Type 2 diabetes.  Expert Opin Investig Drugs
2006, 15:763-778.
8. Todd MK, Watt MJ, Le J, Hevener AL, Turcotte LP: Thiazolidinedi-
ones enhance skeletal muscle triacylglycerol synthesis while
protecting against fatty acid-induced inflammation and insu-
lin resistance.  Am J Physiol Endocrinol Metab 2007, 292:E485-493.
9. Wilding J: Thiazolidinediones, insulin resistance and obesity:
finding a balance.  Int J Clin Pract 2006, 60:1272-1280.
10. Boden G, Zhang M: Recent findings concerning thiazolidinedi-
ones in the treatment of diabetes.  Expert Opin Investig Drugs
2006, 15:243-250.
11. Nunez M, Martin G, Cocca C, Mohamad N, Gutierrez A, Cricco G,
Medina V, Rivera E, Croci M, Crescenti E, et al.: Effect of rosiglita-
zone on N-nitroso-N-methylurea-induced mammary
tumors in rat.  Anticancer Res 2006, 26:2113-2122.
12. Russu WA: Thiazolidinedione anti-cancer activity: is inhibi-
tion of microtubule assembly implicated?  Med Hypotheses
2007, 68:343-346.
13. Chang AJ, Song DH, Wolfe MM: Attenuation of peroxisome pro-
liferator-activated receptor gamma (PPARgamma) medi-
ates gastrin-stimulated colorectal cancer cell proliferation.  J
Biol Chem 2006, 281:14700-14710.
14. Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs
AH, Schlegel U, Heneka MT: Inhibition of in vivo glioma growth
and invasion by peroxisome proliferator-activated receptor
gamma agonist treatment.  Mol Pharmacol 2006, 70:1524-1533.
15. Han S, Roman J: Rosiglitazone suppresses human lung carci-
noma cell growth through PPARgamma-dependent and
PPARgamma-independent signal pathways.  Mol Cancer Ther
2006, 5:430-437.
16. Li MY, Lee TW, Yim AP, Chen GG: Function of PPARgamma and
its ligands in lung cancer.  Crit Rev Clin Lab Sci 2006, 43:183-202.
17. Martelli ML, Iuliano R, Le Pera I, Sama I, Monaco C, Cammarota S,
Kroll T, Chiariotti L, Santoro M, Fusco A: Inhibitory effects of per-
oxisome poliferator-activated receptor gamma on thyroid
carcinoma cell growth.  J Clin Endocrinol Metab 2002,
87:4728-4735.
18. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C,
Malfertheiner P, Farrell GC: Troglitazone inhibits tumor growth
in hepatocellular carcinoma in vitro and in vivo.  Hepatology
2006, 43:134-143.
19. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM,
Thomazy VA, Evans RM: Activators of the nuclear receptor
PPARgamma enhance colon polyp formation.  Nat Med 1998,
4:1058-1061.
20. Seargent JM, Yates EA, Gill JH: GW a potent antagonist of PPAR-
gamma, inhibits growth of breast tumour cells and pro-
motes the anticancer effects of the PPARgamma agonist
rosiglitazone, independently of PPARgamma activation.  Br J
Pharmacol 9662, 143:933-937.
21. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada
MV, Kim L, Kim PJ, Owens RJ, Lang NP: Thiazolidinediones and
the risk of lung, prostate, and colon cancer in patients with
diabetes.  J Clin Oncol 2007, 25:1476-1481.
22. MacLean CD, Littenberg B, Gagnon M, Reardon M, Turner PD, Jordan
C: The Vermont Diabetes Information System (VDIS): study
design and subject recruitment for a cluster randomized
trial of a decision support system in a regional sample of pri-
mary care practices.  Clin Trials 2004, 1:532-544.
23. Gill SC, Butterworth P, Rodgers B, Mackinnon A: Validity of the
mental health component scale of the 12-item Short-Form
Health Survey (MCS-12) as measure of common mental dis-
orders in the general population.  Psychiatry Res 2007 in press.
24. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN: The Self-Admin-
istered Comorbidity Questionnaire: a new method to assess
comorbidity for clinical and health services research.  Arthritis
Rheum 2003, 49:156-163.
25. Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X,
Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E: Comparison
of fingerstick hemoglobin A1c levels assayed by DCA 2000
with the DCCT/EDIC central laboratory assay: results of a
Diabetes Research in Children Network (DirecNet) Study.
Pediatr Diabetes 2005, 6:13-16.
26. MacLean CD, Littenberg B, Kennedy AG: Limitations of diabetes
pharmacotherapy: results from the Vermont Diabetes Infor-
mation System study.  BMC Fam Pract 2006, 7:50.
27. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C,
Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hemat-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2007, 5:17 http://www.biomedcentral.com/1741-7015/5/17
Page 7 of 7
(page number not for citation purposes)
ocrit level after pioglitazone treatment is correlated with
decreased plasma free testosterone level, not hemodilution,
in women with polycystic ovary syndrome.  Clin Pharmacol Ther
2006,  80:105-114.
28. Iatrakis G, Zervoudis S, Saviolakis A, Troulos M, Antoniou E, Saran-
taki A, Lykeridou K, Kourounis G: Women younger than 50
years with endometrial cancer.  Eur J Gynaecol Oncol 2006,
27:399-400.
29. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human
metabolic disease.  J Clin Invest 2006, 116:581-589.
30. Lambert MT, Terrell JE, Copeland LA, Ronis DL, Duffy SA: Ciga-
rettes, alcohol, and depression: characterizing head and
neck cancer survivors in two systems of care.  Nicotine Tob Res
2005, 7:233-241.
31. Ozlu T, Bulbul Y: Smoking and lung cancer.  Tuberk Toraks 2005,
53:200-209.
32. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH:
Inhaled corticosteroids and risk of lung cancer among
patients with chronic obstructive pulmonary disease.  Am J
Respir Crit Care Med 2007, 175:712-719.
33. Caumes JL, Nousbaum JB, Bessaguet C, Faycal J, Robaszkiewicz M,
Gouerou H: Epidemiology of hepatocellular carcinoma in Fin-
istere Prospective study from June 2002 to May 2003.  Gastro-
enterol Clin Biol 2007, 31:259-264.
34. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I:
Sulfonylurea agents exhibit peroxisome proliferator-acti-
vated receptor gamma agonistic activity.  J Biol Chem 2005,
280:23653-23659.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/5/17/prepub